CD8A and neoplasm: Subcutaneously implanted MC38 and CT26 have been treated with 5-FU and oxaliplatin which increased the activity of tumour infiltrating CD8 T cells and prevented exhaustion of the cytotoxic T cells, as they demonstrated lowered expression of inhibitory receptors of PD-1 and TIM-3 [81].